Belgium-based ExeVir announced a $50 million Series A to take the 9-month-old startup’s lead antibody compound XVR011 into a global Phase Ib/II clinical study soon, representing the first in-human trials using a unique, llama-derived antibody.
Centessa, based in Cambridge, Mass. and London, launched as a “novel asset-centric pharmaceutical company.”
Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Switzerland-based Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.
BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
T-knife GmbH, based in Berlin, Germany, closed a €66 million ($78.4 million) Series A round led by Versant Ventures and RA Capital Management.